Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
Immunotherapy Could Be Game Changer In Cancer Treatment
on April 22, 2019 at 3:40 pm
PITTSBURGH (KDKA) — Marilyn McGuigan, Linda Malsh and Claud Lape have had different types of cancer. McGuigan had endometrial cancer. “I had several tumors in my abdomen,” she said. […]
IFN-Gamma Gene Signature Not Linked to Durvalumab/Tremelimumab Benefit in Gastric Cancer
on April 22, 2019 at 2:42 pm
In an interview with OncLive during the 2019 AACR Annual Meeting, Ku, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed these data and shed light on the role of immunotherapy ... […]
Treating Triple-Negative Breast Cancer: What Works, What Doesn’t
on April 22, 2019 at 9:01 am
The Future of Triple-Negative Breast Cancer Treatment Although options are currently limited, new treatment methods are on the horizon. One such option is immunotherapy, which is a type of treatment ... […]
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
on April 22, 2019 at 6:51 am
Merck’s blockbuster immunotherapy has notched FDA approval for treating the most serious cases of kidney cancer. The FDA on Monday approved Merck (NYSE: MRK) drug pembrolizumab (Keytruda ... […]
Innovative drug delivery improves effectiveness of cancer immunotherapy
on April 22, 2019 at 5:53 am
Even after decades of research, cancer remains difficult to treat, in part because of its ability to evade the body’s natural defenses found in the immune system. Immunotherapy, which stimulates the ... […]
Gritstone Oncology Announces Clinical Acceleration of “Off-The-Shelf” Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback
on April 22, 2019 at 5:00 am
... immuno-oncology company developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on key pillars—first, a ... […]
Normalization cancer immunotherapy: blocking Siglec-15!
on April 18, 2019 at 3:18 pm
In a recent paper published in Nature medicine, Wang, J., et al. identified Siglec-15 as a new candidate responsible for adaptive immune resistance and a potential target for normalization cancer ... […]
Physician-scientist recognized for work in cancer genomics and immunotherapy
on April 18, 2019 at 11:02 am
Dr. Antoni Ribas, physician-scientist and professor of medicine in the David Geffen School of Medicine at UCLA, was selected by Agilent Technologies for their Thought Leader Award. The award ... […]
Cancer Immunotherapy Market 2019 Size, Share, Future Growth, Key Players Update, Industry Dynamics, Value, Regional Analysis by 2023
on April 18, 2019 at 6:16 am
Apr 18, 2019 (Heraldkeeper via COMTEX) -- MRFR Leverages its Industry Expertise for Qualitative and Quantitative Analysis of Current Market Trends, Growth Opportunities, Competitive Landscape and ... […]
Cancer Immunotherapy Market to attain a value of US$124.88 billion by 2024 - TMR
on April 15, 2019 at 5:15 am
Albany, NY, Apr 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- Albany, NY, April 15, 2019 (GLOBE NEWSWIRE) -- According to TMR, the global cancer immunotherapy market is estimated to expand at a CAGR of 14.6 ... […]
via Bing News